Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Multiple Myeloma Advanced 2026

Andrew Spencer

安德鲁·斯宾塞

MBBS, FRACP, FRCPA, PhD

🏢Alfred Hospital and Monash University(阿尔弗雷德医院暨莫纳什大学)🌐Australia

Professor of Haematology; Head, Malignant Haematology and Stem Cell Transplantation Unit血液学教授;恶性血液病与干细胞移植单元主任

49
h-index
2
Key Papers
4
Awards
2
Key Contributions

👥Biography 个人简介

Andrew Spencer, MBBS, PhD is Professor of Haematology at Monash University and Head of Malignant Haematology and Stem Cell Transplantation at Alfred Hospital Melbourne. Australia's pre-eminent multiple myeloma researcher, he coordinates ALLG myeloma trials and has led Australian participation in global CAR-T and BCMA-targeted therapy studies. He is a leading voice for equitable access to novel myeloma therapies in Asia-Pacific.

Share:

🧪Research Fields 研究领域

CAR-T Cell Therapy Australia澳大利亚CAR-T细胞治疗
BCMA-Targeted Myeloma TherapyBCMA靶向骨髓瘤治疗
Myeloma Transplantation骨髓瘤移植
Australasian Leukaemia and Lymphoma Group (ALLG)澳大利亚白血病淋巴瘤研究组
Proteasome Inhibitor Combinations蛋白酶体抑制剂联合方案

🎓Key Contributions 主要贡献

BCMA CAR-T and Bispecific Antibody Access in Australia

Championed and led Australian participation in pivotal CAR-T and bispecific antibody trials (CARTITUDE, MajesTEC, KarMMa), establishing Australia as a key site for novel myeloma therapy trials and facilitating TGA approval pathways for BCMA-targeted therapies.

ALLG Myeloma Research Leadership

Coordinates Australasian Leukaemia and Lymphoma Group (ALLG) myeloma program, designing and conducting phase II/III trials tailored to Asia-Pacific patient populations and health system contexts, including lenalidomide access programs and biosimilar daratumumab evaluation.

Representative Works 代表性著作

[1]

Pomalidomide and Dexamethasone with or without Cyclophosphamide in Relapsed and Refractory Multiple Myeloma: An ALLG Trial

British Journal of Haematology (2018)

ALLG MM014 trial defining pomalidomide triplet outcomes in Australian patients with relapsed/refractory myeloma, establishing local practice standards and contributing to global salvage therapy evidence.

[2]

Bortezomib, Thalidomide, and Dexamethasone Followed by Melphalan-Based Autologous Transplantation for Newly Diagnosed Multiple Myeloma

Leukemia & Lymphoma (2014)

Australian multicenter ALLG study reporting long-term outcomes of VTD-ASCT in NDMM, validating European induction standards in Asia-Pacific populations and informing local treatment guidelines.

🏆Awards & Recognition 奖项与荣誉

🏆Haematology Society of Australia and New Zealand (HSANZ) Chesterman Medal
🏆ALLG Distinguished Service Award
🏆Monash University Vice-Chancellor's Award for Excellence in Research
🏆Australian National Health and Medical Research Council (NHMRC) Senior Research Fellowship

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 安德鲁·斯宾塞 的研究动态

Follow Andrew Spencer's research updates

留下邮箱,当我们发布与 Andrew Spencer(Alfred Hospital and Monash University)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment